Authors
Latest:
Combating the Post-Pandemic Pharmacy Workforce ShortageThe pharmaceutical industry is facing a critical talent shortage caused by fewer students entering the field, burnout and a lack of stability. We offer ways to combat the shortage.
Latest:
The Evolution of Precision Medicine in PharmacyPrecision medicine in pharmacy has the potential to revolutionize patient care by optimizing drug selection, dosing, and monitoring.
Latest:
AMCP CEO Raises Concerns Over ACIP Changes, Stresses Pharmacists’ Expanding Public Health RoleSusan Cantrell, RPh, MHL, CAE, CEO of the Academy of Managed Care Pharmacy (AMCP), warns that politicizing the Advisory Committee on Immunization Practices (ACIP) could undermine vaccine trust.
Latest:
EHA 2025: BMS-986458 Shows Clinical Promise in FL and DLBCLFranck Morschhauser, MD, PhD, discusses the novel cereblon-dependent bifunctional degrader BMS-986458, highlighting its selective targeting of BCL6, promising early efficacy in relapsed/refractory lymphoma, favorable safety profile, and future potential in combination regimens and earlier treatment lines.
Latest:
Pharmacists Bridge the Gaps in Care TransitionsFrom admission to discharge and beyond, pharmacists reduce medication errors, improve adherence, and prevent costly readmissions.
Latest:
Understanding the Implications of the FDA’s New Boxed Warning for CAR T-Cell TherapyIn November 2023, the FDA announced an investigation of CAR T-cell therapy based on several reported secondary T-cell malignancies.
Latest:
Introducing Obecabtagene Autoleucel: A New Chapter in ALL TreatmentObecabtagene autoleucel improves CAR T-cell therapy for B-cell ALL.
Latest:
β-Blockers: Big Role or Shrinking Spotlight in Cardiovascular Therapy?Recent studies suggest limited benefit post-myocardial infarction for patients with preserved heart function, prompting potential updates to treatment guidelines and reconsideration of long-term use.
Latest:
Beyond Depression: Antidepressants and Their Diverse IndicationsAn overview of antidepressant medications and their indications to inform health care professionals of their wide use and to better understand which antidepressant to recommend based on patient-specific characteristics.
Latest:
Despite a Lack of US Guidelines, Implementing β-Lactam Therapeutic Drug Monitoring Remains KeyThis step-by-step primer describes the implementation process for β-lactam TDM.
Latest:
A Review of Anti-HER2 Targeted Agents in Non-Breast Solid TumorsThis review summarizes current utilization of anti-HER2 targeted therapy across several non-breast solid tumors in the setting of advanced disease.
Latest:
Fire on the Mountain: Addressing Pharmacy Staff BurnoutThe entire pharmacy profession and all those interested in medication safety need to coalesce around the need for systemic change in community pharmacy workplace environments.
Latest:
CAR T and Beyond: The Expanding Pipeline and Promise of Cell TherapiesWith robust pipelines, cell therapy remains the major driver for drug development.
Latest:
Emerging BCMA-Directed Therapies in Multiple Myeloma: Bispecific Antibodies and CAR T-Cell TherapiesHere is an updated overview of the role of BCMA-directed therapies following the 2024 ASCO Annual Meeting and EHA Congress.
Latest:
Optimizing Self-Management for Outpatient Pharmacy Patients With DiabetesThe use of outpatient pharmacy protocols for glucose testing and insulin administration supplies should be expanded to assist patients in the self-management of diabetes.
Latest:
Treating Acid Reflux With Over-the-Counter MedicationsAn overview of acid reflux and gastroesophageal reflux disease, over-the-counter options, long-term effects of proton pump inhibitors, lifestyle recommendations, and when to refer patients.
Latest:
EHA 2025: Golcadomide Shows Deep Responses in High-Risk Follicular LymphomaJulio C. Chavez, MD, MS, discusses the distinct pharmacologic profile, clinical activity, and outpatient potential of golcadomide plus rituximab in relapsed/refractory follicular lymphoma, highlighting its selective cereblon modulation, fixed-duration dosing, and promising efficacy in heavily pretreated patients.
Latest:
Understand the Impact of the ACA on Women’s Equity and Accessible ContraceptivesAccess to birth control is a crucial part of preventive health care, but financial barriers persist
Latest:
Advice for Optimizing Treatment Success in CLLExperts share final thoughts and advice for clinicians in the community to help optimize treatment success in CLL.
Latest:
The European Medicines Agency: A Modern Robin Hood?Many studies with a stated goal of advancing child health care in administratively-defined minors have no clinical value and may even harm young patients.
Latest:
Two Laws Expand Protections for Nursing EmployeesCreating additional space for nursing mothers can be challenging in small pharmacies
Latest:
RSV Vaccines See a Pricey Leap Forward in Disease PreventionOlder adults without a Part D plan face costs ranging from $180 to $295 per shot.
Latest:
From Shelf to System: Enhancing Digital Visibility in Medication InventoryHealth care automation enhances efficiency, yet medication inventory visibility remains a challenge.
Latest:
Establishing Specialty Pharmacy Beyond US Borders: Opportunities and ChallengesThe 5 largest specialty therapeutic groups—oncology, autoimmune, immunology, HIV, and multiple sclerosis—will account for 74% of specialty spending growth over the next five years.
Latest:
Affordability of Orphan Drugs Hinges on Global CollaborationCross-border collaborations are the way forward to make life-saving treatments more affordable and accessible to patients with rare diseases around the world.
Latest:
Potential for Precision: Exploring Targeted Therapies in mCRC CarePanelists discuss how the importance of having pharmacists embedded in oncology clinics has transformed metastatic colorectal cancer care by enabling real-time decision-making and dose adjustments, while highlighting that these are exciting times with multiple new oral treatment options that patients often prefer over infusions, though managing adherence and side effects remains challenging, and emphasizing that current targeted therapy opportunities include rare but actionable NTRK fusions, HER2 amplifications (3% of cases with multiple treatment options), and KRAS G12C mutations (3% of cases), with future promise in pan-RAS inhibitors, expanded immunotherapy beyond MSI-high tumors, and combination therapies, though dermatologic toxicity from targeted agents like RAS inhibitors will likely be the rate-limiting factor requiring better assessment tools and multidisciplinary management including dermatology support.
Latest:
Global Patient Registries Can Advance Opportunities for Rare Disease ResearchCollaboration and knowledge sharing amongst rare disease researchers can be difficult, as these researchers are often spread out throughout the world.
